Literature DB >> 16950769

The EphB4 receptor-tyrosine kinase promotes the migration of melanoma cells through Rho-mediated actin cytoskeleton reorganization.

Nai-Ying Yang1, Elena B Pasquale, Laurie B Owen, Iryna M Ethell.   

Abstract

Several studies have reported the up-regulation of EphB receptor-tyrosine kinases and ephrin-B ligands in a variety of tumors, suggesting a functional relation between EphB/ephrin-B signaling and tumor progression. The ability of the EphB receptors to regulate cell migration and promote angiogenesis likely contributes to tumor progression and metastasis. Here we show that EphB receptors, and especially EphB4, regulate the migration of murine melanoma cells. Highly malignant melanoma cells express the highest levels of EphB4 receptor and migrate faster than less malignant melanoma cells. Furthermore, inhibition of EphB receptor forward signaling by overexpression of a form of EphB4 lacking the cytoplasmic portion or by treatment with competitively acting soluble EphB2-Fc results in slower melanoma cell migration. In contrast, overexpression of active EphB4 significantly enhances cell migration. The effects of EphB4 receptor on cell migration and cell morphology require its kinase activity because the inhibition of EphB4 kinase activity by overexpression of kinase dead EphB4 inhibits cell migration and affects the organization of actin cytoskeleton. Activation of EphB4 receptor with its ligand ephrin-B2-Fc enhances the migratory ability of melanoma cells and increases RhoA activity, whereas inhibiting EphB receptor forward signaling decreases RhoA activity. Moreover, expression of dominant negative RhoA blocks the effects of active EphB4 on cell migration and actin organization. These data suggest that EphB4 forward signaling contributes to the high migratory ability of invasive melanoma cells by influencing RhoA-mediated actin cytoskeleton reorganization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16950769     DOI: 10.1074/jbc.M604338200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.

Authors:  Benjamin D Ferguson; Maria S Tretiakova; Mark W Lingen; Parkash S Gill; Ravi Salgia
Journal:  Growth Factors       Date:  2014-11-13       Impact factor: 2.511

2.  The EphB4 receptor promotes the growth of melanoma cells expressing the ephrin-B2 ligand.

Authors:  Nai-Ying Yang; Pablo Lopez-Bergami; James S Goydos; Dana Yip; Ameae M Walker; Elena B Pasquale; Iryna M Ethell
Journal:  Pigment Cell Melanoma Res       Date:  2010-07-23       Impact factor: 4.693

Review 3.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

Authors:  Elena B Pasquale
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

Review 4.  Essential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis.

Authors:  Ombretta Salvucci; Giovanna Tosato
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

5.  Ephrin-B2 elicits differential growth cone collapse and axon retraction in retinal ganglion cells from distinct retinal regions.

Authors:  Timothy J Petros; J Barney Bryson; Carol Mason
Journal:  Dev Neurobiol       Date:  2010-09-15       Impact factor: 3.964

Review 6.  Eph- and ephrin-dependent mechanisms in tumor and stem cell dynamics.

Authors:  Erika Gucciardo; Nami Sugiyama; Kaisa Lehti
Journal:  Cell Mol Life Sci       Date:  2014-05-04       Impact factor: 9.261

Review 7.  The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.

Authors:  Jill Wykosky; Waldemar Debinski
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

Review 8.  Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms.

Authors:  Suzanne Eccles; Lenaic Paon; Jonathan Sleeman
Journal:  Clin Exp Metastasis       Date:  2007-11-06       Impact factor: 5.150

9.  Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4.

Authors:  Srinivas Duggineni; Sayantan Mitra; Roberta Noberini; Xiaofeng Han; Nan Lin; Yan Xu; Wang Tian; Jing An; Elena B Pasquale; Ziwei Huang
Journal:  Biochem Pharmacol       Date:  2012-12-17       Impact factor: 5.858

10.  Staurosporine augments EGF-mediated EMT in PMC42-LA cells through actin depolymerisation, focal contact size reduction and Snail1 induction - a model for cross-modulation.

Authors:  Honor J Hugo; Razan Wafai; Tony Blick; Erik W Thompson; Donald F Newgreen
Journal:  BMC Cancer       Date:  2009-07-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.